Medicinal use of cannabis based products and cannabinoids
BMJ 2019; 365 doi: https://doi.org/10.1136/bmj.l1141 (Published 04 April 2019) Cite this as: BMJ 2019;365:l1141
All rapid responses
Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles or when it is brought to our attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not including references and author details. We will no longer post responses that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
Apart from the authors not knowing their delta-8 THC from their delta-9 THC, this is a good succinct summary of cannabis based medicinal products. Lennox-Gastaut syndrome is misspelt in the text, and it is incorrect to refer to ‘spice’ as an example of a synthetic cannabinoid receptor agonist (SCRA). Spice is now a generic street term for SCRAs, it’s like referring to ‘ecstasy’ as an example of MDMA.
Competing interests: No competing interests
It's delta-*9*-tetrahydrocannabinol (not 8) that is in Sativex and should probably be referred to here https://www.medicines.org.uk/emc/product/602
Competing interests: No competing interests
Re: Medicinal use of cannabis based products and cannabinoids
Errors in the spelling of delta-9-tetrahydrocannabinol and Lennox-Gastaut syndrome were introduced in print and these have now been resolved. We have clarified that "Spice" is an example of a product containing synthetic cannabinoid receptor agonists.
Competing interests: No competing interests